Duchenne muscular dystrophy - disease characterization and emergent genetic therapy - literature review
DOI:
https://doi.org/10.12775/QS.2025.43.62338Keywords
gene therapy, Duchenne muscular dystrophy, Duchenne muscular dystrophy therapyAbstract
Introduction
The goals of this paper are to present the complexity of Duchenne muscular dystrophy phenotype, genetic background, and substantial progress that has been made due to the development of genetic engineering techniques in diagnosing and treating this condition.
Review methods
A thorough review was conducted using the PubMed database, Google Scholar, and relevant subject literature. The paper focused on presenting the latest knowledge available from research on etiology, the course of the disease, and new trends in the treatment of Duchenne muscular dystrophy.
Summary
Duchenne muscular dystrophy, despite being mainly associated with motoric difficulties, is connected with abnormalities in other areas, even cognitive function. Thanks to progress in genetic engineering, new opportunities have emerged in DMD treatment, including the application of several genetic therapies: adeno-associated virus (AAV) vectors, CRISPR-Cas9, termination codon read-through, and exon skipping agents.
Conclusions
Newly emerging medications, acting at the genetic level through various mechanisms, provide hope for further advances in Duchenne muscular dystrophy treatment. Although the application of gene therapy showed a noticeable effect, it was still not satisfactory. At this moment, the most reasonable approach is combined therapy with glucocorticosteroids, interdisciplinary care, and the introduction of a selected type of gene therapy.
References
1. Orphanet: Duchenne muscular dystrophy [(Accessed on 3 May 2025)]
2. Blake DJ, Weir A, Newey SE, Davies KE. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev. 2002 Apr;82(2):291-329. doi: 10.1152/physrev.00028.2001.
3. Brenman JE, Chao DS, Xia H, Aldape K, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell. 1995 Sep 8;82(5):743-52. doi: 10.1016/0092-8674(95)90471-9. PMID: 7545544.
4. Nallamilli, B. R. R., Chaubey, A., Valencia, C. A., Stansberry, L., Behlmann, A. M., Ma, Z., Mathur, A., Shenoy, S., Ganapathy, V., Jagannathan, L., Ramachander, V., Ferlini, A., Bean, L., & Hegde, M. (2021). A single NGS-based assay covering the entire genomic sequence of the DMD gene facilitates diagnostic and newborn screening confirmatory testing. Human Mutation, 42, 626–638. https://doi.org/10.1002/humu.24191
5. Fortunato F, Farnè M, Ferlini A. The DMD gene and therapeutic approaches to restore dystrophin. Neuromuscul Disord. 2021 Oct;31(10):1013-1020. doi: 10.1016/j.nmd.2021.08.004.
6. Koenig M, Beggs AH, Moyer M, Scherpf S, Heindrich K, Bettecken T, Meng G, Müller CR, Lindlöf M, Kaariainen H, de la Chapellet A, Kiuru A, Savontaus ML, Gilgenkrantz H, Récan D, Chelly J, Kaplan JC, Covone AE, Archidiacono N, Romeo G, Liechti-Gailati S, Schneider V, Braga S, Moser H, Darras BT, Murphy P, Francke U, Chen JD, Morgan G, Denton M, Greenberg CR, Wrogemann K, Blonden LA, van Paassen MB, van Ommen GJ, Kunkel LM. The molecular basis for Duchenne versus Becker muscular dystrophy: correlation of severity with type of deletion. Am J Hum Genet. 1989 Oct;45(4):498-506.
7. Potulska-Chromik A, Aragon-Gawinska K. Duchenne muscular dystrophy. In: Kopyta I,(Ed.).Child neurology in a pediatrician's practice. 1st ed. Warszawa:PZWL 2022; 149-154. Polish
8. Ricotti V, Mandy WP, Scoto M, Pane M, Deconinck N, Messina S, Mercuri E, Skuse DH, Muntoni F. Neurodevelopmental, emotional, and behavioural problems in Duchenne muscular dystrophy in relation to underlying dystrophin gene mutations. Dev Med Child Neurol. 2016 Jan;58(1):77-84. doi: 10.1111/dmcn.12922.
9. 1.Gosar D, Košmrlj L, Musek PL, Meško T, Stropnik S, Krkoč V, Golli T, Butenko T, Loboda T, Osredkar D. Adaptive skills and mental health in children and adolescents with neuromuscular diseases. Eur J Paediatr Neurol. 2021 Jan;30:134-143. doi: 10.1016/j.ejpn.2020.10.008.
10. Yang JH, Kim KS, Lee GH, Kim HS. Comparison of survival analysis between surgical and non-surgical treatments in Duchenne muscular dystrophy scoliosis. Spine J. 2020 Nov;20(11):1840-1849. doi: 10.1016/j.spinee.2020.06.004.
11. Boland BJ, Silbert PL, Groover RV, Wollan PC, Silverstein MD. Skeletal, cardiac, and smooth muscle failure in Duchenne muscular dystrophy. Pediatr Neurol. 1996 Jan;14(1):7-12. doi: 10.1016/0887-8994(95)00251-0.
12. Wahlgren L, Kroksmark AK, Lindblad A, Tulinius M, Sofou K. Respiratory comorbidities and treatments in Duchenne muscular dystrophy: impact on life expectancy and causes of death. J Neurol. 2024 Jul;271(7):4300-4309. doi: 10.1007/s00415-024-12372-7.
13. Lott DJ, Taivassalo T, Cooke KD, Park H, Moslemi Z, Batra A, Forbes SC, Byrne BJ, Walter GA, Vandenborne K. Safety, feasibility, and efficacy of strengthening exercise in Duchenne muscular dystrophy. Muscle Nerve. 2021 Mar;63(3):320-326. doi: 10.1002/mus.27137.
14. Patterson G, Conner H, Groneman M, Blavo C, Parmar MS. Duchenne muscular dystrophy: Current treatment and emerging exon skipping and gene therapy approach. Eur J Pharmacol. 2023 May 15;947:175675. doi: 10.1016/j.ejphar.2023.175675.
15. Duan D. Duchenne Muscular Dystrophy Gene Therapy in 2023: Status, Perspective, and Beyond. Hum Gene Ther. 2023 May;34(9-10):345-349. doi: 10.1089/hum.2023.29242.ddu.
16. Duan D. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy. Curr Opin Mol Ther. 2008 Feb;10(1):86-94.
17. Secord E, Hartog NL. Review of Treatment for Adenosine Deaminase Deficiency (ADA) Severe Combined Immunodeficiency (SCID). Ther Clin Risk Manag. 2022 Sep 22;18:939-944. doi: 10.2147/TCRM.S350762.
18. Hoffman-Zacharska D, Charzewska A. Gene therapy for inherited monogenic diseases. In: Bal J,(Ed.).Medical and molecular genetics. 2nd ed. Warszawa: Wydawnictwo Naukowe PWN. 2023;465-478. Polish
19. Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9.
20. Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, Corti M, Byrne BJ, Tremblay JP. Current Clinical Applications of In Vivo Gene Therapy with AAVs. Mol Ther. 2021 Feb 3;29(2):464-488. doi: 10.1016/j.ymthe.2020.12.007.
21. Bowles DE, McPhee SW, Li C, Gray SJ, Samulski JJ, Camp AS, Li J, Wang B, Monahan PE, Rabinowitz JE, Grieger JC, Govindasamy L, Agbandje-McKenna M, Xiao X, Samulski RJ. Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector. Mol Ther. 2012 Feb;20(2):443-55. doi: 10.1038/mt.2011.237.
22. England SB, Nicholson LV, Johnson MA, Forrest SM, Love DR, Zubrzycka-Gaarn EE, Bulman DE, Harris JB, Davies KE. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature. 1990 Jan 11;343(6254):180-2. doi: 10.1038/343180a0.
23. Happi Mbakam C, Lamothe G, Tremblay G, Tremblay JP. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. Neurotherapeutics. 2022 Apr;19(3):931-941. doi: 10.1007/s13311-022-01197-9.
24. Duan D. Systemic AAV Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy. Mol Ther. 2018 Oct 3;26(10):2337-2356. doi: 10.1016/j.ymthe.2018.07.011. Epub 2018 Jul 17.
25. Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, Kissel JT, Nagendran S, L'Italien J, Sproule DM, Wells C, Cardenas JA, Heitzer MD, Kaspar A, Corcoran S, Braun L, Likhite S, Miranda C, Meyer K, Foust KD, Burghes AHM, Kaspar BK. Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy. N Engl J Med. 2017 Nov 2;377(18):1713-1722. doi: 10.1056/NEJMoa1706198.
26. Shoti J, Qing K, Keeler GD, Duan D, Byrne BJ, Srivastava A. Development of capsid- and genome-modified optimized AAVrh74 vectors for muscle gene therapy. Mol Ther Methods Clin Dev. 2023 Nov 2;31:101147. doi: 10.1016/j.omtm.2023.101147.
27. Philippidis A. After patient death, FDA places hold on Pfizer Duchenne muscular dystrophy gene therapy trial. Human Gene Therapy, 2022, 33.3-4: 111-115.
28. Lek A, Wong B, Keeler A, Blackwood M, Ma K, Huang S, Sylvia K, Batista AR, Artinian R, Kokoski D, Parajuli S, Putra J, Carreon CK, Lidov H, Woodman K, Pajusalu S, Spinazzola JM, Gallagher T, LaRovere J, Balderson D, Black L, Sutton K, Horgan R, Lek M, Flotte T. Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy. N Engl J Med. 2023 Sep 28;389(13):1203-1210. doi: 10.1056/NEJMoa2307798.
29. Hoy SM. Delandistrogene Moxeparvovec: First Approval. Drugs. 2023 Sep;83(14):1323-1329. doi: 10.1007/s40265-023-01929-x.
30. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science. 2007 Mar 23;315(5819):1709-12. doi: 10.1126/science.1138140.
31. Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments. Cells. 2024 May 8;13(10):800. doi: 10.3390/cells13100800.
32. Happi Mbakam C, Lamothe G, Tremblay G, Tremblay JP. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. Neurotherapeutics. 2022 Apr;19(3):931-941. doi: 10.1007/s13311-022-01197-9.
33. Brunner E, Yagi R, Debrunner M, Beck-Schneider D, Burger A, Escher E, Mosimann C, Hausmann G, Basler K. CRISPR-induced double-strand breaks trigger recombination between homologous chromosome arms. Life Sci Alliance. 2019 Jun 13;2(3):e201800267. doi: 10.26508/lsa.201800267.
34. Leibowitz ML, Papathanasiou S, Doerfler PA, Blaine LJ, Sun L, Yao Y, Zhang CZ, Weiss MJ, Pellman D. Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing. Nat Genet. 2021 Jun;53(6):895-905. doi: 10.1038/s41588-021-00838-7.
35.European Medicines Agency. Translarna. https://www.ema.europa.eu/en/medicines/human/EPAR/translarna [(Accessed on 17 May 2025)]
36. Clemens PR, Niizawa G, Feng J, Florence J, DʼAlessandro AS, Morgenroth LP, Gorni K, Guglieri M, Connolly A, Wicklund M, Bertorini T, Mah JK, Thangarajh M, Smith E, Kuntz N, McDonald CM, Henricson EK, Upadhyayula S, Byrne B, Manousakis G, Harper A, Bravver E, Iannaccone S, Spurney C, Cnaan A, Gordish-Dressman H; CINRG BNHS Investigators. The CINRG Becker Natural History Study: Baseline characteristics. Muscle Nerve. 2020 Sep;62(3):369-376. doi: 10.1002/mus.27011.
37. Takeda S, Clemens PR, Hoffman EP. Exon-Skipping in Duchenne Muscular Dystrophy. J Neuromuscul Dis. 2021;8(s2):S343-S358. doi: 10.3233/JND-210682.
38. Wang F, Zuroske T, Watts JK. RNA therapeutics on the rise. Nat Rev Drug Discov. 2020 Jul;19(7):441-442. doi: 10.1038/d41573-020-00078-0.
39. Shadid M, Badawi M, Abulrob A. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion. Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1281-1292. doi: 10.1080/17425255.2021.1992382.
40. Syed YY. Eteplirsen: First Global Approval. Drugs. 2016 Nov;76(17):1699-1704. doi: 10.1007/s40265-016-0657-1.
41. Heo YA. Golodirsen: First Approval. Drugs. 2020 Feb;80(3):329-333. doi: 10.1007/s40265-020-01267-2.
42. Dhillon S. Viltolarsen: First Approval. Drugs. 2020 Jul;80(10):1027-1031. doi: 10.1007/s40265-020-01339-3.
43. Shirley M. Casimersen: First Approval. Drugs. 2021 May;81(7):875-879. doi: 10.1007/s40265-021-01512-2.
44. Han B, Shieh PB. Safety, tolerability, and pharmacokinetics of casimersen in patients with Duchenne muscular dystrophy amenable to exon 45 skipping: A randomized, double-blind, placebo-controlled, dose-titration trial. Muscle Nerve. 2021 Sep;64(3):285-292. doi: 10.1002/mus.27347.
45. Clemens PR, Rao VK, Connolly AM, Harper AD, Mah JK, Smith EC, McDonald CM, Zaidman CM, Morgenroth LP, Osaki H, Satou Y, Yamashita T, Hoffman EP; CINRG DNHS Investigators. Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A Phase 2 Randomized Clinical Trial. JAMA Neurol. 2020 Aug 1;77(8):982-991. doi: 10.1001/jamaneurol.2020.1264. Erratum in: JAMA Neurol. 2020 Aug 1;77(8):1040. doi: 10.1001/jamaneurol.2020.2025
46. Mehta N, Gilbert R, Chahal PS, Moreno MJ, Nassoury N, Coulombe N, Lytvyn V, Mercier M, Fatehi D, Lin W, Harvey EM, Zhang LH, Nazemi-Moghaddam N, Elahi SM, Ross CJD, Stanimirovic DB, Hayden MR. Preclinical Development and Characterization of Novel Adeno-Associated Viral Vectors for the Treatment of Lipoprotein Lipase Deficiency. Hum Gene Ther. 2023 Sep;34(17-18):927-946. doi: 10.1089/hum.2023.075.
47. McDonald C, Camino E, Escandon R, Finkel RS, Fischer R, Flanigan K, Furlong P, Juhasz R, Martin AS, Villa C, Sweeney HL. Draft Guidance for Industry Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Related Dystrophinopathies - Developing Potential Treatments for the Entire Spectrum of Disease. J Neuromuscul Dis. 2024;11(2):499-523. doi: 10.3233/JND-230219.
48. Cordova G, Negroni E, Cabello-Verrugio C, Mouly V, Trollet C. Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. Front Genet. 2018 Apr 10;9:114. doi: 10.3389/fgene.2018.00114.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Anna Teresa Michalska, Michał Świda, Cezary Kubuj, Grzegorz Adaśko, Urszula Mazur, Jakub Bazarewicz, Marcin Siwik, Daniel Dmowski, Paulina Ogonowska, Julia Waszak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 358
Number of citations: 0
